WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 206166
Description: PFK-158, also known as ACT-PFK-158, is an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFK-2/FBPase) isoform 3 (PFKFB3) with potential antineoplastic activity. Upon administration, PFKFB3 inhibitor PFK-158 binds to and inhibits the activity of PFKFB3, which leads to the inhibition of both the glycolytic pathway in and glucose uptake by cancer cells. This prevents the production of macromolecules and energy that causes the enhanced cellular proliferation in cancer cells as compared to that of normal, healthy cells. Depriving cancer cells of nutrients and energy leads to the inhibition of cancer cell growth.
MedKoo Cat#: 206166
Chemical Formula: C18H11F3N2O
Exact Mass: 328.08235
Molecular Weight: 328.29
Elemental Analysis: C, 65.85; H, 3.38; F, 17.36; N, 8.53; O, 4.87
PFK-158, purity > 98%, is in stock.
Synonym: PFK158; PFK 158; PFK158; ACTPFK158.
IUPAC/Chemical Name: (E)-1-(pyridin-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)prop-2-en-1-one
InChi Key: IAJOMYABKVAZCN-AATRIKPKSA-N
InChi Code: InChI=1S/C18H11F3N2O/c19-18(20,21)14-3-1-12-2-4-15(23-16(12)11-14)5-6-17(24)13-7-9-22-10-8-13/h1-11H/b6-5+
SMILES Code: O=C(C1=CC=NC=C1)/C=C/C2=NC3=CC(C(F)(F)F)=CC=C3C=C2
The following data is based on the product molecular weight 328.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Zhang Y, Wang X, Li X, Dong L, Hu X, Nie T, Lu Y, Lu X, Pang J, Li G, Yang X,
Li C, You X. Synergistic Effect of Colistin Combined with PFK-158 against
Colistin-Resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2019 Jun
24;63(7). pii: e00271-19. doi: 10.1128/AAC.00271-19. Print 2019 Jul. PubMed PMID:
30988150; PubMed Central PMCID: PMC6591609.
2: Mondal S, Roy D, Sarkar Bhattacharya S, Jin L, Jung D, Zhang S, Kalogera E,
Staub J, Wang Y, Xuyang W, Khurana A, Chien J, Telang S, Chesney J, Tapolsky G,
Petras D, Shridhar V. Therapeutic targeting of PFKFB3 with a novel glycolytic
inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers.
Int J Cancer. 2019 Jan 1;144(1):178-189. doi: 10.1002/ijc.31868. Epub 2018 Oct
30. Erratum in: Int J Cancer. 2019 Jul 15;145(2):E13. PubMed PMID: 30226266;
PubMed Central PMCID: PMC6261695.
The PFKFB enzymes (PFKFB 1- 4) synthesize fructose-2,6-bisphosphate (F2,6BP) which activates 6-phosphofructo-l- kinase (PFK-1), an essential control point in the glycolytic pathway. Neoplastic cells preferentially utilize glycolysis to satisfy their increased needs for energy and biosynthetic precursors. Malignant tumor cells have glycolytic rates that are up to 200 times higher than those of their normal tissues of origin. One cancer attack strategy has been to treat cancer by starving cancerous cells in various ways. Reducing or blocking the enhanced glycolytic flux mechanism present in cancer cells has stimulated recent interest. Despite greater understanding and pharmaceutical advances in the diagnosis and treatment of cancer, it is still estimated that nearly 13% of all human deaths last year were due to cancer. Thus, there remains a need for safe and effective anti-cancer therapeutics, particularly those which target neoplastic cells via mechanisms such as glycolytic flux, which are over-expressed in cancer cells. (http://www.google.com/patents/WO2013148228A1?cl=en)